Volume 74, Issue 2, Pages (August 2018)

Slides:

Advertisements

Similar presentations

Volume 69, Issue 5, Pages (May 2016)

Advertisements

Volume 62, Issue 4, Pages (October 2012)

The PSA Era is not Over for Prostate Cancer

Volume 50, Issue 1, Pages (July 2006)

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 53, Issue 4, Pages (April 2008)

Volume 61, Issue 5, Pages (May 2012)

Volume 53, Issue 5, Pages (May 2008)

Volume 51, Issue 4, Pages (April 2007)

Louis Spencer Krane, Mahendra Bhandari, James O. Peabody, Mani Menon

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 63, Issue 4, Pages e53-e56 (April 2013)

Volume 63, Issue 2, Pages (February 2013)

Volume 65, Issue 5, Pages (May 2014)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

Volume 54, Issue 4, Pages (October 2008)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 53, Issue 4, Pages (April 2008)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Volume 67, Issue 3, Pages (March 2015)

Volume 56, Issue 2, Pages (August 2009)

Volume 66, Issue 3, Pages (September 2014)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 70, Issue 5, Pages (November 2016)

Volume 71, Issue 6, Pages (June 2017)

Counselling the Prostate Cancer Patient

Volume 73, Issue 4, Pages (April 2018)

Volume 54, Issue 2, Pages (August 2008)

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Leonard S. Marks, Jiaoti Huang European Urology

Volume 53, Issue 4, Pages (April 2008)

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 58, Issue 1, Pages 1-7 (July 2010)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 74, Issue 2, Pages (August 2018)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 71, Issue 3, Pages (March 2017)

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 71, Issue 4, Pages (April 2017)

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 69, Issue 5, Pages (May 2016)

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 74, Issue 2, Pages 140-143 (August 2018) Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes Chad A. Reichard, Justin R. Gregg, Mary F. Achim, Ana M. Aparicio, Curtis A. Pettaway, Louis L. Pisters, John F. Ward, John W. Davis, Brian F. Chapin European Urology Volume 74, Issue 2, Pages 140-143 (August 2018) DOI: 10.1016/j.eururo.2018.03.031 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Percentage of PSA change from PSA nearest prior to RP and PSA nearest after RP in the setting of mCRPC. Patients who died during follow up are circled. mCRPC=metastatic castration-resistant prostate cancer; PSA=prostate-specific antigen; RP=radical prostatectomy. a Corresponds to patient number in Table 1. European Urology 2018 74, 140-143DOI: (10.1016/j.eururo.2018.03.031) Copyright © 2018 European Association of Urology Terms and Conditions